Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence


In this video, David A. Ginsberg, MD, discusses the takeaways of the study, “Long-term, repeat treatments with onabotulinumtoxinA are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.

Related Videos
Illustration of AI | Image Credit: © Tierney - stock.adobe.com
DNA illustration | Image Credit: © BillionPhotos.com - stock.adobe.com
Mara R. Holton, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Illustration of kidney stones | Image Credit: © freshidea - stock.adobe.com
United States Capitol Building | Image Credit: © rrodrickbeiler - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.